Kythera Biopharmaceuticals, Inc.
30930 Russell Ranch Road
KYTHERA is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Our objective is to develop first-in-class, prescription products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. Our initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is currently in late-stage clinical development for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. KYTHERA submitted its New Drug Application for ATX-101 in May 2014, which the FDA has determined will be subject to a standard review and will have a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.
OUR FOUNDING: KYTHERA Biopharmaceuticals was founded in 2005 on the premise on building a new kind of biotechnology company – one aimed squarely at bringing great science, clinical rigor and real innovation to the growing area of aesthetic medicine.
OUR INSPIRATION: KYTHERA Biopharmaceuticals, Inc. is named after an island off the coast of southern Greece, in the Mediterranean Sea. Southernmost of the Ionian Islands, the island of Kythera was the chief center for the worship of Aphrodite, the Greek goddess of beauty and love. Our colors symbolize sky blue and sand.
OUR MANAGEMENT TEAM: We have a highly experienced management team, many of whom have played a leadership role in securing FDA approval of marquee aesthetic products, such as BOTOX® and JUVEDERM®, and in successfully commercializing established biotechnology products such as Aranesp®, NEUPOGEN® and Neulasta®.